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Introduction
A vaccine to prevent hepatitis C virus (HCV) infection is urgently 
needed. Although recently developed direct-acting antivirals are 
highly effective for HCV treatment, most individuals are unaware of 
their infection status, so they do not seek treatment and may continue 
to expose others (1, 2). Most infected persons do not have access to 
direct-acting antivirals, and treatment does not prevent reinfection 
after cure (3–7). Unfortunately, HCV vaccine development has been 
hampered by incomplete understanding of correlates of protective 
immunity in humans (8, 9) and by inadequate methods for assessing 
antibody responses induced by candidate vaccines.
Around 25% of individuals who are acutely infected with HCV 
spontaneously clear the infection without treatment (10). We and 
others have shown that this spontaneous clearance is associated 
with early development of broadly neutralizing plasma, suggest-
ing that identifying neutralizing antibodies (NAbs) present in the 
plasma of these individuals could elucidate the NAbs that should 
be induced by a vaccine (11, 12). However, the epitope specifici-
ties of NAbs present in broadly neutralizing plasma are unknown. 
This plasma might contain NAbs similar to known broadly neu-
tralizing monoclonal antibodies (bNmAbs), broadly neutraliz-
ing antibodies (bNAbs) with novel epitopes, or a diverse array of 
strain-specific NAbs.
Available methods used to identify the epitopes targeted 
by polyclonal serum-neutralizing antibodies have notable lim-
itations. One such method is isolating monoclonal antibodies 
(mAbs) from B cells. We and others have isolated bNmAbs from 
the B cells of individuals who cleared HCV infection (13–17), 
and we demonstrated that bNmAbs designated HEPC3 and 
HEPC74, which target the front layer of envelope protein E2 
(E2), contributed to viral clearance in 2 individuals by driving 
the infecting virus to an unfit state (18). However, these bNmAbs 
may not fully represent the complete repertoire of polyclonal 
NAbs present in the plasma of these subjects before viral clear-
ance, and these methods remain relatively labor intensive and 
time consuming, making it difficult to characterize a large 
number of subjects. One alternative approach is measurement 
of serum antibody binding to peptide arrays, but many NAbs 
bind to discontinuous, conformational epitopes rather than 
linear peptides (9, 19, 20). A third approach is measurement of 
envelope protein 1 and 2–binding (E1/E2-binding) competition 
between serum antibodies and reference mAbs (21), but these 
assays are confounded by the abundance of E1/E2 binding but 
nonneutralizing antibodies in plasma. These nonneutralizing 
antibodies may compete with bNmAbs for overlapping or adja-
cent E1/E2 epitopes (22–27), so binding competition may not 
discriminate reliably between neutralizing and nonneutralizing 
antibodies in plasma. Given these limitations, previous studies 
have not comprehensively identified NAbs contributing to neu-
tralizing breadth of plasma or NAbs that may be associated with 
clearance or persistence of HCV infection.
In this article, we present the development and application of 
a high-throughput method that delineates the epitope specificities 
of anti-HCV NAbs in polyclonal human plasma. Using this method, 
we show that the majority of anti-HCV plasma neutralizing activity 
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tralization profiles could be used to deconvolute HCV-specific 
NAbs in polyclonal plasma.
To deconvolute HCV-specific NAbs in plasma, we measured 
neutralization of the 19-HCVpp panel by plasma samples at a 1:100 
or 1:20 dilution, generating a neutralization profile for each sample 
(Figure 1). To analyze these data, we adapted an algorithm devel-
oped by Georgiev et al. for deconvolution of HIV-specific NAbs 
(31). This algorithm adds reference mAb neutralization profiles 
in all possible proportions to generate an array of combined refer-
ence mAb neutralization profiles. The algorithm then identifies the 
combined reference mAb neutralization profile with the minimum 
difference from the plasma neutralization profile, thereby delineat-
ing the most likely proportion of each reference mAb contributing 
to the neutralization profile of the plasma sample.
We added an additional step to the algorithm to quantitate 
quality of fit of each plasma deconvolution (see Methods and Sup-
plemental Figure 1; supplemental material available online with 
this article; https://doi.org/10.1172/JCI130720DS1). For this qual-
ity analysis, we added reference mAb neutralization profiles in the 
proportions determined by the deconvolution and then compared 
the resulting combined mAb neutralization profile with the cor-
responding plasma neutralization profile using Pearson’s correla-
tion. A deconvolution was considered a good fit if the P value of 
this correlation was less than 0.05.
Selection of a mAb reference panel for plasma deconvolution. Many 
mAbs targeting distinct epitopes on HCV E1/E2 have been isolated 
from the B cells of HCV-infected humans, but it is not known which 
of these mAbs might contribute to plasma neutralizing activity. To 
identify the most comprehensive, least redundant mAb reference 
panel for plasma deconvolution analysis, we analyzed our previ-
ously tested set of 20 mAbs. This set includes mAbs specific for 
a variety of epitopes on E1 and/or E2 (Figure 2A), and it includes 
in individuals with subsequent clearance or persistence of HCV 
can be attributed to a set of NAbs with known epitope specificities. 
Notably, focusing of the immune response toward bNAbs rather 
than narrow-breadth NAbs and simultaneous expression of mul-
tiple bNAb types was associated with greater plasma neutralizing 
breadth and with HCV clearance. These studies inform new strat-
egies for vaccine development by identifying bNAb combinations 
in plasma associated with HCV clearance, while also providing a 
high-throughput assay that could identify these responses after 
vaccination trials.
Results
Deconvolution method. We previously measured neutralization 
of a diverse panel of 19 genotype 1a and 1b HCV pseudoparticles 
(HCVpp) by 20 anti-HCV human mAbs (13, 28). The HCVpp panel 
was selected to maximize genetic diversity among functional 
genotype 1 HCV E1/E2 genes, and it contains 94% of amino 
acid polymorphisms present at greater than 5% frequency in 
genotype 1 HCV isolates from GenBank (https://www.ncbi.nlm.
nih.gov/genbank/) (29, 30). We have previously observed con-
cordance between the neutralization breadth of mAbs measured 
using this diverse genotype 1 panel and neutralizing breadth of 
the same mAbs measured using HCV strains from genotypes 
1–6 (13, 16, 30). Each mAb exhibited a distinct ranking of rela-
tive neutralization potency across the HCVpp in the panel, also 
known as a neutralization fingerprint or neutralization profile. 
The neutralization profile of each mAb was unique and repro-
ducible, and these neutralization profiles also could be used to 
cluster functionally similar mAbs into groups (28). Subsequently, 
we observed that plasma samples from persons infected with 
HCV also exhibited distinct neutralization profiles across the 
HCVpp panel (18), leading us to hypothesize that these neu-
Figure 1. Deconvolution method. Neutralization of a panel of 19 HCVpp by 8 reference mAbs or 63 plasma samples was measured, generating a neutraliza-
tion profile (i.e., ranking of relative neutralization of each HCVpp) for each reference mAb (“mAb rank”) and each plasma sample (“plasma rank”). Points 
on each graph represent the ranking of relative neutralization sensitivity of each of 19 HCVpp by plasma on the x axis and a reference mAb on the y axis. 
Reference mAb neutralization profiles were added in all possible proportions to generate an array of possible combined mAb neutralization profiles (“com-
bined mAb rank”). The algorithm then identified the specific combined reference mAb neutralization profile with the minimum difference from each plasma 
neutralization profile, thereby delineating the most likely proportion of each reference mAb contributing to the neutralization profile of the plasma sample.
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formed NAb type 2. As we have previously noted, this analysis also 
revealed some functional relationships among mAbs that were not 
predicted by their binding sites (28). Some mAbs, which are thought 
to bind to distinct antigenic sites, like HC-1 and CBH-7, appeared 
to be functionally related, forming a single NAb type (Nab type 4). 
Conversely, some mAbs binding to partially overlapping epitopes, 
like AR3A and HC-1 (36, 37), segregated into distinct NAb types 
(NAb type 1 and NAb type 4, respectively). Some of these unex-
pected functional relationships are due to shared resistance muta-
tions outside of the defined epitopes, which likely mediate indirect 
effects by allosteric means (28, 38–40). Overall, these data confirm 
that neutralization profiles can be used to identify individual mAbs 
or groups of mAbs with closely related binding epitopes.
Based on correlations between neutralization profiles, 18 
mAbs segregated into 6 NAb types including 2 to 4 mAbs each, 
some of the most broadly neutralizing mAbs described to date, as 
well as mAbs with more limited neutralizing breadth (Figure 2B 
and refs. 13, 19, 20, 26, 32, 33). To cluster this set of mAbs into NAb 
types based on functional similarity, we calculated pairwise Pear-
son correlations between mAb neutralization profiles, and mAbs 
were grouped if the neutralization profile of each mAb in the group 
had a correlation (r) greater than or equal to 0.55 (P < 0.02) with 
the profile of every other mAb in the group (Figure 2C and Supple-
mental Figure 2). At this r-value threshold, most mAbs with highly 
similar binding sites fell into the same group, and most mAbs with 
clearly distinct binding sites fell into distinct groups. For example, 
mAbs AR3A, AR3B, AR3C, and AR3D, which bind overlapping epi-
topes on E2 and compete for E2 binding (19, 34, 35), formed NAb 
type 1. HC33.4, HC33.8, and HEPC98, which each bind near the 
N-terminus of E2, and also compete for E2 binding (13, 26, 27), 
Figure 2. Selection of a reference mAb panel. 
(A) Main-chain atoms of previously defined mAb 
binding residues identified by alanine-scanning 
mutagenesis (see Methods) marked with colored 
spheres on the crystallized structure of the HCV E2 
protein ectodomain (gray), strain 1b09, PDB acces-
sion 6MEI (15), with colors modified in PyMOL, 
v1.8.6.2. For clarity, a maximum of 5 residues 
with impact on binding of each mAb are marked. 
Antigenic domains/antigenic regions (ARs) are 
indicated, and mAbs highlighted with the same 
color share multiple binding residues. Dashed lines 
indicate a disordered region (HVR1) or part of the 
E2 protein truncated to aid crystallization (stem 
region of E2). Putative AR4A and AR5A binding 
residues on E1 are not shown. (B) Neutralizing 
breadth of reference mAbs at 10 μg/mL mea-
sured with a panel of 19 genotype 1 HCVpp, with 
a threshold of 50% neutralization considered 
positive. (C) Functional grouping of reference 
mAbs. For each mAb, neutralization of each of 
19 HCVpp was measured in duplicate, generating 
a neutralization profile (i.e., ranking of relative 
neutralization of each HCVpp) (Supplemental 
Figure 2), and pairwise Pearson correlations were 
measured between these neutralization profiles. 
Circles at each intersection of the heatmap are 
scaled by the magnitude of the correlation (r) 
between the indicated NAbs. mAbs were grouped 
into an NAb type if the neutralization profile of 
each mAb in the group had a correlation of greater 
than or equal to 0.55 with every other mAb in the 
group. One representative mAb (indicated with an 
asterisk) was selected from each NAb type to form 
the final panel of 8 reference mAbs.
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We also tested 2 different combinations of 3 mAbs. When HC-1, 
CBH-2, and AR3A were combined at equivalent concentrations, 
all 3 mAbs were identified in the deconvolution analysis at pro-
portions of 0.26, 0.22, and 0.53, respectively. HEPC98, HEPC74, 
and HC84.26 also were identified correctly in combination, with 
proportions of 0.26, 0.33, and 0.34, respectively. Taken together, 
these data confirm that deconvolution analysis can identify indi-
vidual mAbs alone or in polyclonal mixtures, although some 
mAbs, such as AR1A, may be more difficult to detect in a mixture 
with other mAbs.
Because low-level false-positive proportions were identified in 
some samples, we set a true-positive threshold proportion greater 
than 0.1, which resulted in 95% sensitivity and 100% specificity 
in Figure 3 experiments. Proportions greater than 0.1 were consid-
ered positive in all subsequent analyses.
Because neutralization profiles are a relative ranking of neu-
tralization of HCVpp by each NAb, rather than absolute neutraliza-
tion values, we hypothesized that deconvolution results would be 
consistent across multiple mAb concentrations. To test this hypoth-
esis, we performed deconvolution analysis using neutralization 
profile results measured using 2 different concentrations of each 
reference mAb (Supplemental Figure 3). The deconvolution result 
for each mAb was consistent at either 10 or 2 μg/mL mAb concen-
trations (50 or 10 μg/mL for AR1A), confirming that neutralization 
profiles remain consistent even when percentage neutralization 
values are very low. Notably, narrow-breadth mAbs AR1A, HC-1, 
and CBH-2 were correctly identified based on relative neutraliza-
tion of HCVpp across the panel even at concentrations of 2 to 10 
μg/mL, when each mAb neutralized only 0 or 1 of 19 HCVpp in the 
panel by more than 50%, and 3 to 6 HCVpp by more than 25%.
Concordance between plasma NAb deconvolution and mAbs iso-
lated from B cells of the same subject. To validate the plasma deconvo-
lution method by a second approach, we performed deconvolution 
analysis on plasma of 2 human donors, subjects C117 and C110, 
from whom we had previously isolated mAbs from peripheral 
blood B cells (Figure 4). C117 was the donor of B cells producing 
reference mAb HEPC98 as well as mAbs designated HEPC3 and 
and 2 mAbs, CBH-2 and AR1A, did not group with other mAbs 
(Figure 2C). To select the mAb reference panel for plasma 
deconvolution analysis, we identified the most functionally dis-
tinct representative of each NAb type. This was the mAb from 
each group with the neutralization profile that had the lowest 
correlations with the neutralization profiles of mAbs from other 
NAb types. This analysis selected a reference panel comprising 
the following 8 mAbs: AR3A, HEPC98, HEPC74, HC-1, AR4A, 
HC84.26, CBH-2, and AR1A. Notably, reference mAbs in this set 
exhibited a range of neutralizing breadth, from 3 of 19 HCVpp 
neutralized by 10 μg/mL of AR1A to 17 of 19 HCVpp neutralized 
by 10 μg/mL of AR4A. For the purposes of this study, we defined 
bNAbs as NAbs capable of neutralizing greater than or equal to 
10 of 19 HCVpp by greater than 50% when tested at 10 μg/mL 
concentrations and narrow-breadth NAbs as NAbs neutralizing 
less than 10 of 19 HCVpp under these same conditions. By these 
criteria, 4 of 8 reference mAbs were bNAbs (AR4A, HC84.26, 
HEPC74, and AR3A) and 4 of 8 were narrow-breadth NAbs 
(AR1A, HC-1, HEPC98, and CBH-2).
Deconvolution of samples containing known mAbs. To validate 
the mAb reference panel and deconvolution method, we repeated 
neutralization testing against the 19-HCVpp panel with single- 
reference mAbs or combinations of reference mAbs. We then used 
these neutralization profiles as input into the deconvolution algo-
rithm (Figure 3). As expected, deconvolution analysis correctly 
identified the mAb present in each single-mAb sample. Notably, 
these experiments confirmed that the deconvolution method 
can reliably discriminate between each of the 8 reference mAbs, 
including AR3A, HEPC74, HC84.26, CBH-2, and HC-1, which tar-
get overlapping epitopes in the E2 front layer. We also analyzed 
samples containing combinations of 2 or 3 reference mAbs, with 
each reference mAb included in at least 1 combination. All mAbs 
except AR1A were identified correctly in the 2-mAb combinations 
of HC-1+AR3A, CBH-2+AR3A, and AR1A+AR4A. Notably, pro-
portions assigned to each mAb in the 2-mAb combinations were 
not equivalent, although the mAbs were combined at equivalent 
concentrations, likely reflecting relative potency of the mAbs. 
Figure 3. Deconvolution of samples containing known 
mAbs. Neutralization profiles of samples containing 
single-reference mAbs or combinations of reference mAbs 
were used as input into the deconvolution algorithm. Each 
2- or 3-mAb combination included 5 μg/mL or 3.3 μg/mL 
of each mAb, respectively. These neutralization profiles 
were determined in a single experiment, with neutraliza-
tion of each HCVpp measured in duplicate. Reference mAb 
profiles were averaged from 4 or 5 independent experi-
ments. Values are the proportion of the neutralization 
activity of the sample attributed to each reference mAb by 
the deconvolution analysis. Proportions greater than 0.10 
are highlighted in gray. P values indicate the Pearson cor-
relation of the neutralization profiles of spiked-in mAbs  
with a combined reference mAb neutralization profile 
comprising the indicated proportion of each reference 
mAb (see Methods and Supplemental Figure 1).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 7 9 0 jci.org   Volume 129   Number 11   November 2019
Neutralization profiles from 10 of 12 mAbs isolated from C18 
B cells correlated significantly with profiles of reference mAb 
types identified in plasma by the deconvolution analysis (AR1A, 
AR3A, or AR4A), which was significantly greater than the concor-
dance between C18 plasma NAbs and C18 B cell mAbs expected 
by chance (83% vs. 44%, P = 0.007 by binomial test, see Methods). 
Nine of 12 C18 mAbs (75%) shared both neutralization profiles 
and E1/E2 binding residues with reference mAb types identified 
in plasma by the deconvolution analysis. In addition, E1/E2 bind-
ing residues of C18 B cell mAbs were 7.5-fold more likely to fall at 
binding residues of reference mAb types identified in plasma by 
deconvolution analysis than at other residues in E1 or E2 (P < 1 × 
10–15 by Fisher’s exact test).
Three of 12 C18 B cell mAbs (25%) were not predicted by the 
plasma deconvolution analysis. Two C18 mAbs matched best with 
reference mAb HEPC74, which was not detected in plasma. In 
addition, C18 mAb HEPC112 did not share E1/E2 binding residues 
with any reference mAb, although the HEPC112 neutralization 
profile correlated strongly with reference mAb AR1A. This cor-
relation between neutralization profiles of AR1A and HEPC112 is 
explained in part by the strong bias of each mAb for neutralization 
of genotype 1a strains over 1b strains, indicating that this method 
may falsely attribute some genotype 1a–biased plasma NAb 
responses to AR1A-type NAbs. HEPC98-type NAbs were identi-
fied in plasma but not isolated from B cells, which may indicate 
a false-positive plasma deconvolution result or the relative ineffi-
ciency of mAb isolation.
Overall, 9 of 12 C18 mAbs isolated from B cells (75%) matched 
plasma deconvolution-identified reference mAbs by both neutral-
ization profiles and binding residues. Figure 5C shows the location 
on the E2 structure of probable binding residues of 3 reference 
mAb types identified in C18 plasma by the deconvolution analysis 
(AR1A, AR3A, AR4A) and 3 C18 mAbs with which each had a posi-
tively correlated neutralization profile and shared binding residues 
(HEPC151-2, HEPC154, HEPC130). Taken together, these data 
indicate that the NAb types detected in plasma by the deconvolu-
tion analysis were strongly predictive of both the functional pheno-
types and E1/E2 binding residues of mAbs subsequently isolated 
from B cells of the same subject.
Deconvolution of NAb types in plasma of humans with subsequent 
clearance or persistence of HCV infection. For a prior study, we used 
HEPC84, which are HEPC74-type or AR4A-type NAbs, respec-
tively (Figure 2 and ref. 13). Therefore, we hypothesized that we 
should detect HEPC98-type, HEPC74-type, and AR4A-type NAbs 
in C117 plasma. C110 was the donor of B cells producing refer-
ence mAb HEPC74, so we hypothesized that we should detect 
HEPC74-type NAbs in C110 plasma. For each subject, we analyzed 
plasma obtained prior to HCV clearance, using the averaged neu-
tralization profiles obtained using 1:20 and 1:100 dilutions of each 
plasma sample as input into the deconvolution analysis (see Meth-
ods). As expected, HEPC98-type, HEPC74-type, and AR4A-type 
NAbs were each identified in C117 plasma (proportions = 0.12, 
0.40, and 0.34, respectively), and HEPC74-type NAbs were iden-
tified in C110 plasma (proportion = 0.36). Notably, HC-1–type, 
HC84.26-type, and HEPC98-type NAbs were also detected in C110 
plasma (proportions = 0.27, 0.16, and 0.10, respectively), although 
they were not isolated from the subject’s B cells, which may reflect 
false-positive plasma deconvolution results or the relative ineffi-
ciency of mAb isolation. Taken together, these results show that 
mAbs isolated from the B cells of 2 subjects also were identified in 
the plasma of the same subjects by deconvolution analysis.
To further validate the deconvolution method, we prospectively 
deconvoluted the plasma NAbs of a different HCV-positive subject, 
designated C18, using an average of neutralization profiles obtained 
using 1:20 and 1:100 dilutions of plasma as input into the deconvolu-
tion analysis. We then isolated mAbs from B cells of the same subject 
(Figure 5). Unlike C117 and C110, some of the neutralizing activity 
in C18 plasma was attributed to AR1A-type and AR3A-type NAbs 
(proportions 0.16 and 0.13, respectively), with the remainder of 
activity attributed to HEPC98-type and AR4A-type NAbs (propor-
tions 0.37 and 0.33, respectively) (Figure 5A). We recently described 
isolation and characterization of 13 mAbs from B cells of this sub-
ject (16). In that study, 12 of 13 mAbs displayed neutralizing activity 
across the HCVpp panel at a 50 μg/mL concentration. We measured 
neutralization profiles for these 12 mAbs, and we also mapped up to 
15 (range, 3 to 15) probable E1/E2-binding residues for each C18 mAb 
and reference mAb based on binding to a comprehensive alanine 
mutant library spanning the E1 and E2 proteins of strain H77. Here, 
we identified the reference mAb (AR1A, HC-1, CBH-2, HEPC98, 
AR3A, HEPC74, HC84.26, or AR4A) that was most similar to each 
C18 mAb based on neutralization profile correlations and/or shared 
probable E1/E2 binding residues (Figure 5B).
Figure 4. Concordance between plasma deconvolution and mAbs 
isolated from B cells of the same subject. Deconvolution of NAb 
types in plasma of 2 subjects, C117 and C110, from whom reference 
mAbs were also isolated from B cells. Plasma neutralization profiles 
were averaged from 2 independent experiments, which were each 
performed in duplicate. Reference mAb profiles were averaged 
from 5 independent experiments, with each performed in duplicate. 
Wedge sizes are proportional to the plasma response attributed 
to each reference mAb. **Reference mAb detected in plasma was 
isolated from the B cells of the same subject. *Reference mAb 
detected in plasma and a mAb isolated from the B cells of this sub-
ject are of the same NAb type (i.e., they have positively correlated 
neutralization profiles and compete for E1/E2 binding). P values are 
for Pearson correlations of each plasma neutralization profile with 
a combined reference mAb neutralization profile comprising the indi-
cated proportion of each reference mAb.
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the HCVpp panel to measure neutralizing breadth of plasma sam-
ples isolated from 21 subjects with subsequent clearance of HCV 
infection and 42 subjects with subsequent persistence of infection 
(11). Age, sex, race, follow-up interval, HCV infection genotype, 
and interferon-λ 3–related rs12979860 allele frequencies were 
similar between these persistence and clearance groups, as pre-
viously described (11). Plasma was isolated from clearance sub-
jects at the last viremic time point before infection clearance, and 
plasma from subjects in the persistence groups was time matched 
with the clearance plasma samples for the duration of infection. 
That study demonstrated that acute-infection plasma from clear-
ance subjects was significantly more broadly neutralizing than 
plasma from subjects in the persistence group. We applied the 
deconvolution method to identify the NAbs responsible for this 
plasma neutralizing breadth.
Neutralization profiles of these 63 plasma samples were aver-
aged from neutralization results measured in independent exper-
iments at 1:20 and 1:100 plasma dilutions, and we used these 
neutralization profiles to deconvolute NAb types present in the 
samples (Figure 6). Forty-four (70%) of the samples (persistence 
n = 29, clearance n = 15) had a good fit in the deconvolution anal-
ysis (P < 0.05), suggesting that the neutralizing activity of these 
samples could be attributed to 1 or more of the mAb types in our 
reference panel. The proportion of subjects with good fit in the 
deconvolution analysis did not differ significantly between the 
persistence and clearance groups (69% vs. 71%, P = 1, Fisher’s 
exact test). Results for samples with poor fit in the deconvolution 
analysis are shown in Supplemental Figure 4. Although we could 
not identify the NAbs present in these samples with confidence, 
the samples with poor fit displayed very low neutralizing breadth 
(mean breadth = 1 of 19 HCVpp neutralized), indicating that the 
poor fit could more likely be explained by absent or very low-titer 
bNAbs in these samples, rather than the presence of novel bNAbs 
not represented by the reference mAb panel.
We performed all subsequent analyses using only data from 
the plasma samples with good fit in the deconvolution analysis 
(Figures 7 and 8). A significantly higher proportion of the antibody 
response was devoted to narrow-breadth HC-1–type NAbs in per-
sistence subjects relative to clearance subjects (mean persistence 
vs. clearance proportions 0.28 vs. 0.14, P = 0.03 by 1-way ANOVA 
adjusted for multiple comparisons) (Figure 7A). The mean pro-
portion of the antibody response devoted to each bNAb type (i.e., 
Figure 5. Plasma NAb deconvolution predicts 
mAbs subsequently isolated from B cells of the 
same subject. (A) NAb deconvolution of subject 
C18 plasma. Plasma neutralization profile was 
averaged from 2 independent experiments. Refer-
ence mAb profiles were averaged from 5 indepen-
dent experiments. Wedge sizes are proportional to 
the plasma response attributed to each reference 
mAb. P value is from the Pearson correlation 
of the C18 plasma neutralization profile with a 
combined neutralization profile comprising the 
indicated proportion of each reference mAb. (B) 
Pearson correlations between neutralization pro-
files and number of shared probable E1/E2-binding 
residues, as determined by alanine-scanning 
mutagenesis–E1/E2-binding analysis, between 12 
mAbs isolated from subject C18 B cells and best-
match reference mAbs. C18 mAb neutralization 
profiles were determined in a single experiment, 
with neutralization of each HCVpp measured in 
duplicate. (C) Examples of concordance between 
binding residues of reference mAbs identified in 
plasma and 3 best-match mAbs isolated from 
C18 B cells. Colored spheres indicated main chain 
atoms of probable binding residues, superimposed 
on the crystallized structure of the HCV E2 protein 
ectodomain, strain 1b09, PDB accession 6MEI (15), 
with colors modified in PyMOL, v1.8.6.2. Shared 
putative E1 binding residues of HEPC130 and AR4A 
(Y201, N205) are not shown.
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AR3A, HEPC74, HC84.26, or AR4A) was similar for persistence 
and clearance subjects, although there was a trend toward a higher 
proportion for each bNAb type in clearance relative to persistence 
subjects. Taken together, these data indicate that focusing of the 
immune response toward narrow-breadth HC-1–type NAbs was 
associated with the persistence of HCV infection, and no single 
NAb type was strongly associated with HCV clearance.
Given prior data from our group and others indicating that 
some bNAbs in combination are synergistic with enhanced 
neutralizing breadth (16, 41, 42), we hypothesized that combi-
nations of bNAbs, rather than individual responses, might be 
associated with HCV clearance. Therefore, we compared the 
total proportion of the neutralizing response devoted to bNAbs 
(i.e., sum of AR4A, HC84.26, HEPC74, and AR3A proportions) 
in clearance or persistence subjects (Figure 7B). Remarkably, we 
measured significantly higher total bNAb proportions in clear-
ance vs. persistence subjects (mean proportion, 0.62 vs. 0.46; P = 
0.009 by 2-tailed t test). Although the total number of reference 
NAb types detected per plasma sample did not differ between 
clearance and persistence groups (mean = 3.5 vs. 3.2 NAb types, 
P = 0.24 by 2-tailed t test) (Figure 7C), we detected a signifi-
cantly higher number of distinct bNAb types per plasma sample 
in clearance vs. persistence subjects (mean no. of bNAb types 
per sample 2.1 vs. 1.6, P = 0.04 by 2-tailed t test) (Figure 7D). 
The most common 2 bNAb combinations detected in clearance 
plasma were HEPC74+AR4A (6 of 15 subjects), AR3A+AR4A (5 
of 15 subjects), and HC84.26+AR4A (3 of 15 subjects) (Figure 
7E). These data indicate that focusing of the humoral response 
toward bNAbs rather than narrow-breadth NAbs and simultane-
ous expression of multiple bNAb types in a single plasma sample 
was associated with HCV clearance.
Focusing of the humoral response toward bNAbs and expression 
of multiple bNAb types was associated with greater plasma neutral-
izing breadth. To investigate the mechanism by which focusing 
of the humoral response toward bNAbs and expression of mul-
tiple bNAb-types was associated with infection clearance, we 
measured the association between these parameters and plasma 
neutralizing breadth. First, we compared neutralizing breadth of 
persistence and clearance plasma samples, limiting the analysis to 
samples with good fit in the deconvolution analysis (Figure 8A). 
We observed significantly greater neutralizing breadth by the 
clearance samples (mean no. of HCVpp neutralized by 1:100 dilu-
tion of clearance vs. persistence plasma 7.3 vs. 3.1, P = 0.003 by 
2-tailed t test), which was consistent with our prior analysis of the 
full set of 63 plasma samples (11).
Next, we measured the correlation between the total bNAb 
proportion of each plasma sample (i.e., sum of AR4A, HC84.26, 
HEPC74, and AR3A proportions) and the neutralizing breadth of 
that sample (Figure 8B). We observed a statistically significant 
positive correlation between these variables (r = 0.39, P = 0.01 
by Pearson’s method). Notably, we also observed a significant 
correlation between the number of bNAb types expressed in 
each plasma sample and the neutralizing breadth of that sample 
(Figure 8C). The mean neutralizing breadth of plasma samples 
expressing 1 or fewer bNAb types, 2 bNAb types, or 3 bNAb types 
was 2.1, 5.3, or 8 HCVpp neutralized, respectively (P = 0.004 for 
the trend by 1-way ANOVA). Taken together, these data indicate 
that focusing of the humoral response toward bNAbs rather than 
narrow-breadth NAbs and simultaneous expression of multiple 
bNAb types was associated with greater plasma neutralizing 
breadth as well as clearance of HCV infection.
Figure 6. Deconvolution of NAbs in plasma of subjects with subsequent 
clearance or persistence of HCV infection. Reference mAbs are on the 
x axis with plasma samples on the y axis. Each plasma sample is from a 
different subject. Plasma neutralization profiles each were averaged from 
2 independent experiments. Reference mAb profiles were averaged from 5 
independent experiments. Values shown are the proportion of each plasma 
neutralizing response attributed to each reference mAb. Proportions greater 
than 0.1 are shown and marked with different colors for each NAb type, 
with higher values shaded darker. Plasma samples are grouped by subject 
outcome. Neutralizing breadth was calculated as the number out of 19 
HCVpp neutralized greater than 50% by a 1:100 dilution of plasma. P values 
are for the Pearson correlation between the plasma sample neutralization 
profile and the best-fit combined reference mAb neutralization profile. Only 
subjects with significant correlation (P < 0.05) between combined mAb neu-
tralization profile and plasma neutralization profile are shown (persistence  
n = 29, clearance n = 15). Results for subjects with a poor deconvolution fit 
are shown in Supplemental Figure 4.
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were induced at the expense of more broadly neutralizing E2 front 
layer–specific antibodies. Targeting of more variable epitopes at the 
expense of more conserved, broadly neutralizing epitopes, com-
monly known as deceptive imprinting, has been described previ-
ously for HIV-1 and influenza (46). Alternatively, HC-1–type NAbs 
may represent an early response that could mature to a HEPC74 
or AR3A-like response with appropriate T cell help. Further longi-
tudinal studies of human subjects with persistent infection will be 
necessary to discriminate between these possibilities. Notably, tra-
ditional methods used to map epitopes of vaccine-induced NAbs, 
such as E1/E2 binding competition between serum and reference 
mAbs, would likely not discriminate between the desired E2 front 
layer–specific bNAbs and less desirable narrow-breadth HC-1–type 
NAbs targeting the same antigenic site. This deconvolution method 
also provides a considerable advantage relative to postvaccination 
neutralizing breadth testing alone because breadth might result 
from targeting of 1 or multiple epitopes. In contrast, deconvolu-
tion analysis identifies the epitopes targeted, which could facili-
tate rational antigen design and iterative vaccine improvement to 
favor induction of bNAb combinations associated with clearance of 
natural infection. Fortunately, this method is high throughput and 
requires only about 100 μL of plasma, so it would be ideal for test-
ing longitudinal plasma samples or for optimizing vaccine protocols 
when only small plasma volumes can be obtained.
Discussion
HCV vaccine development has been hampered by incomplete 
understanding of correlates of protective immunity in humans 
and by inadequate methods for assessing antibody responses 
induced by candidate vaccines. We have addressed these deficits 
through the development of an assay that deconvolutes the anti-
HCV NAbs in polyclonal plasma. Unexpectedly, we found that 
most human subjects with subsequent clearance or persistence of 
HCV infection developed at least 1 bNAb during acute infection. 
Importantly, focusing of the humoral response toward bNAbs 
rather than narrow-breadth NAbs and simultaneous expression of 
multiple bNAb types was associated with greater plasma neutral-
izing breadth and with HCV clearance.
These results support prior work indicating that HCV vaccines 
should induce multiple bNAb types (19, 41–43), and we extend 
these findings by demonstrating that it may be important to induce 
HEPC74, AR3A, or HC84.26-like bNAbs in combination with AR4A-
like bNAbs, while avoiding induction of more narrow-breadth NAbs 
like HC-1. Broadly neutralizing AR3A, HEPC74, and HC84.26 as 
well as relatively narrow-breadth HC-1 and CBH-2 bind to over-
lapping conformational epitopes, which may complicate efforts to 
induce 1 NAb type without the other. It is possible that this compli-
cation has played a role in the relatively limited neutralizing breadth 
induced by candidate vaccines to date (44, 45), if HC-1–type NAbs 
Figure 7. Focusing of the humoral response toward bNAbs and expression of multiple bNAb types was associated with HCV clearance. (A) Proportion of 
persistence and clearance plasma responses attributed to each NAb type. Values are means, and error bars are SEM. *P < 0.05 by 1-way ANOVA adjusted 
for multiple comparisons using Sidak’s method. (B) Total proportion of persistence and clearance plasma responses attributed to bNAbs (AR3A, HEPC74, 
HC84.26, or AR4A). Horizontal lines are means, and whiskers are SD. **P < 0.01 by 2-sided t test. (C) Number of NAb types positive above a threshold 
of 0.10 for each plasma sample. Horizontal lines are means, and whiskers are SD. P = 0.24 by 2-sided t test. (D) Number of bNAb types (AR3A, HEPC74, 
HC84.26, or AR4A) positive above a threshold of 0.10 for each plasma sample. Horizontal lines are means, and whiskers are SD. *P < 0.05 by 2-sided t test. 
(E) Frequency of each observed bNAb combination across all persistence or clearance subjects.
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plasma neutralizing breadth and with HCV clearance. These stud-
ies inform new strategies for vaccine development by identifying 
bNAb combinations in plasma associated with clearance of HCV, 
while also providing a high-throughput assay that could identify 
these responses after vaccination trials.
Methods
Study subjects. Plasma samples and PBMCs were obtained from sub-
jects in the Baltimore Before and After Acute Study of Hepatitis 
(BBAASH) cohort (10).
Source of mAbs. MAbs CBH-2, CBH-7, HC-1, CBH-5 (48), HC84.22, 
HC84.26 (20), HC33.4, and HC33.8 (26) were a gift from Steven Foung 
(Stanford University School of Medicine, Palo Alto, California, USA). 
mAbs AR1A, AR2A, AR3A, AR3B, AR3C, AR3D (19), AR4A, and AR5A 
(32) were a gift from Mansun Law (Scripps Research Institute, La Jolla, 
California, USA). All other antibodies were isolated in the laboratory 
of James E. Crowe Jr. (13, 16).
Cell lines. HEK293T cells and Hep3B cells were obtained from 
ATCC.
HCVpp neutralization assay. HCVpp were produced by lipo-
fectamine-mediated transfection of HCV E1/E2, pNL4-3.Luc.R-E, 
and pAdVantage (Promega) plasmids into HEK293T cells as previ-
ously described (28, 49, 50). Neutralization assays were performed 
as described previously (51, 52). mAbs at 10 or 50 μg/mL, or heat- 
inactivated plasma samples at 1:100 or 1:20 dilution were incubated 
with HCVpp for 1 hour at 37°C prior to addition to Hep3B cells in dupli-
cate. Medium was changed after 5 hours, and cells were incubated for 72 
hours before measuring luciferase activity in cell lysates in relative light 
units (RLUs). Only HCVpp preparations producing at least 1 × 106 RLU 
were used for neutralization experiments, and HCVpp input was 
normalized to 1 × 106 to 6 × 106 RLUs. Nonspecific human IgG (Sigma- 
Aldrich) at 50 μg/mL was used as a negative control. Fraction unaf-
fected (Fu) was calculated by the formula: Fu = RLUsmAb or RLUsplasma/ 
RLUsnonspecific IgG. Fu values were converted to a neutralization profile 
for each mAb or plasma sample (rank order of HCVpp neutralization 
with the most sensitive HCVpp ranked 1 and the least sensitive HCVpp 
ranked 19) for input into the deconvolution algorithm.
Deconvolution of NAb specificities in plasma. Neutralization of a 
diverse panel of 19 genotype 1 HCVpp (strains 1a09, 1a31, 1a38, 1a53, 
This method has limitations. First, it is likely that epitopes 
and function of NAbs developing in different individuals do not 
exactly match the reference mAbs to which they are most closely 
related. These subtle differences may have important functional 
implications, so there is still a critical role for isolation of additional 
mAbs from B cells of HCV-infected or vaccinated subjects, which 
will allow molecular and structural characterization of protective 
or deleterious NAb-epitope interactions. The deconvolution assay 
likely can be improved iteratively by adding unique reference mAbs 
when they are identified and through the use of larger and more 
diverse HCVpp panels, which would likely improve discrimination 
between functionally related NAbs. Second, the assay appeared 
to favor detection of more potent NAbs over less potent NAbs, 
and therefore proportions of the neutralizing response attributed 
to individual mAbs in combination experiments did not always 
directly correlate with the relative concentrations of those mAbs 
in the mixture. Further standardization of the assay to quantitate 
actual concentrations of individual NAb types in plasma might 
therefore be difficult and would at minimum, require extensive 
testing of multiple-reference mAb combinations with each mAb at 
multiple different concentrations. The assay does not detect non-
neutralizing antibodies, which may also play a role in controlling 
infection (47), or in shaping the NAb response by competing with 
NAbs for overlapping epitopes on E1 and E2 (22–27). The NAbs that 
were detected infrequently in this study may be rare in plasma, or 
they may be present but effectively out-competed for E2 binding by 
nonneutralizing antibodies. Further work is needed to understand 
this relationship between neutralizing and nonneutralizing anti-
bodies against HCV. Finally, this method does not measure plasma 
neutralizing titers, which likely also play an important role in the 
outcome of infection.
In summary, we developed a method that deconvolutes anti-
HCV NAbs in polyclonal plasma, and we used this method to 
identify NAb types in acute plasma infection of human subjects 
with subsequent clearance or persistence of HCV. We found that 
no single Nab type was strongly associated with HCV clearance. 
Remarkably, however, focusing of the humoral response toward 
bNAbs rather than narrow-breadth NAbs and simultaneous 
expression of multiple bNAb types was associated with greater 
Figure 8. Focusing of the humoral response toward bNAbs and expression of multiple bNAb types was associated with greater plasma neutralizing 
breadth. (A) Neutralizing breadth of plasma samples from subjects in the persistence or clearance group (no. out of 19 HCVpp neutralized > 50% by a 
1:100 dilution of plasma). (B) Correlation between total proportion of each plasma response attributed to bNAbs and neutralizing breadth of that plasma 
sample. P and r values were calculated by Pearson’s method. (C) Relationship between the number of bNAb types expressed by each plasma sample and 
neutralizing breadth of that sample. **P < 0.01 for the trend by 1-way ANOVA.
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an individual point mutant, covering 552 of 555 target E1/E2 residues. 
Binding of each mAb to WT E1/E2 and to each of these alanine mutants 
was quantitated to identify up to 15 residues where mutation to alanine 
mediated the greatest reduction in mAb binding and also reduced 
binding by at least 50% relative to binding to WT H77 E1/E2. Probable 
binding residues of reference mAbs were identified through re-analysis 
of primary data included in prior publications (13, 36, 37, 48).
Statistics. Statistical analyses were performed in Prism (GraphPad 
Software, v7.02). Correlations between plasma and reference mAb 
neutralization profiles were calculated using Pearson’s method. Pro-
portion of persistence and clearance plasma responses attributed to 
each NAb type was compared by 1-way ANOVA adjusted for multiple 
comparisons using Sidak’s method. The total proportion of persistence 
and clearance plasma responses attributed to bNAbs and numbers of 
NAb types per sample was compared by 2-sided t tests. The relation-
ship between the number of bNAb types expressed and neutralizing 
breadth of samples was analyzed by 1-way ANOVA. For all compari-
sons, P values less than 0.05 were considered significant. Probability 
of concordance between neutralization profiles of NAb types identi-
fied in C18 plasma and mAbs isolated from B cells arising by chance 
was calculated using a binomial test and the null hypothesis that each 
mAb isolated would fall by chance in 1 of 9 groups, either matching 
1 of the 8 reference mAbs, or none of them. The significance of the 
increased likelihood of C18 mAb binding residues falling at binding 
residues of deconvolution-identified reference mAbs was calculated 
using Fisher’s exact test and the following data: 8 to 15 binding resi-
dues were identified for each of 12 C18 mAbs; 3 to 15 binding residues 
were known for each of 4 mAbs identified in plasma; and there were 
552 possible E1/E2 binding residues for each mAb.
Study approval. The protocol was approved by the Institutional 
Review Board of the Johns Hopkins Hospital, and informed consent 
was obtained from all study participants.
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1a72, 1a80, 1a116, 1a123, 1a129, 1a142, 1a154, 1a157, 1b09, 1b14, 1b21, 
1b34, 1b38, 1b52, and 1b58) by 20 HCV-specific mAbs at 10 μg/mL 
concentration was quantitated for prior studies, generating a neutral-
ization profile for each mAb, as previously described (13, 28). Once the 
final panel of 8 reference mAbs was selected, neutralization profiles 
were measured for each of these mAbs in 4 additional independent 
experiments. Neutralization profiles for each reference mAb were 
averaged across all 5 experiments by averaging the rank value for each 
HCVpp across all experiments, generating a final neutralization pro-
file for each reference mAb (Supplemental Table 1). Plasma samples 
from subjects with clearance (n = 21) or persistence (n = 42) of HCV 
infection were previously tested at a 1:100 dilution for neutralization 
of the same 19 HCVpp panels (11), except that HCVpp 1b21 and 1a116 
were replaced by closely related HCVpp 1b20 (differing from 1b21 by 
1 aa) and 1a114 (differing from 1a116 by 10 aa), due to greater avail-
ability of these HCVpp stocks at the time of testing. Because reference 
mAbs were not tested against 1b20 and 1a114, plasma neutralization 
results for these HCVpp were not included in neutralization profiles 
used for deconvolution analysis. The same plasma samples were 
tested in a second independent experiment at a 1:20 dilution for neu-
tralization of the same 19-HCVpp panel used to determine reference 
mAb neutralization profiles, including strains 1a116 and 1b21. Neutral-
ization data for 8 HCVpp (1b34, 1a53, 1b38, 1a123, 1a80, 1b58, 1a142, 
and 1b14) were discarded from this second experiment due to inade-
quate HCVpp infectivity (<1 × 106 RLU). Neutralization profiles were 
averaged across these 2 independent experiments to generate a final 
neutralization profile for each plasma sample (Supplemental Table 2). 
Deconvolution analysis was performed using code developed by Geor-
giev et al. (31) (in Wolfram Mathematica, v. 11.0) to delineate the rela-
tive proportion of each reference mAb present in each plasma sample. 
Rank order of plasma neutralization profiles were reversed before 
analysis to fit input requirements of the deconvolution program.
Calculating fit of plasma deconvolution. (See example calculation, 
Supplemental Figure 1.) For each plasma sample deconvolution, a 
scaled neutralization profile was calculated for each reference mAb 
by multiplying the neutralization profile of that reference mAb by 
the proportion of that mAb type (range, 0–1) calculated to be pres-
ent in the plasma sample. These 8 scaled reference mAb neutraliza-
tion profiles then were added to generate a combined reference mAb 
neutralization profile. This combined reference mAb neutralization 
profile was compared with the actual plasma neutralization profile by 
Pearson’s correlation. NAb deconvolution for any plasma sample was 
considered a good fit if the correlation between the combined mAb 
neutralization profile and the plasma neutralization profile had a P 
value less than 0.05 by 2-sided test.
Shotgun mutagenesis epitope mapping. Epitope mapping of mAbs 
was previously described (16, 34). Briefly, comprehensive alanine- 
scanning mutagenesis of an expression construct for HCV E1/E2 (gen-
otype 1a, strain H77) changed each residue to alanine (with alanine res-
idues changed to serine) to create a library of clones, each representing 
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